Denali Therapeutics Inc. $DNLI Shares Acquired by Baillie Gifford & Co.

Key Points

• Baillie Gifford & Co. increased its stake in Denali Therapeutics by 6.2% in Q4, buying 719,304 shares to hold 12,310,889 shares — roughly 8.39% of the company, valued at about $203.3 million; institutional investors now own ~92.92% of DNLI.
• Wall Street sentiment is broadly positive with multiple firms (Morgan Stanley, Stifel, Goldman Sachs, UBS) raising price targets and an average target of $35 ("Moderate Buy"), although HC Wainwright substantially cut long‑range EPS forecasts for FY2027–FY2030, adding longer‑term uncertainty.
• Shares trade around $19.23 with a market cap of $3.05 billion and a negative P/E; Denali reported a Q that beat estimates modestly (EPS of ($0.73) vs. ($0.75) est.), reflecting ongoing development‑stage losses despite pipeline progress.

Baillie Gifford & Co. lifted its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,310,889 shares of the company's stock after buying an additional 719,304 shares during the quarter. Baillie Gifford & Co. owned approximately 8.39% of Denali Therapeutics worth $203,253,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in DNLI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Denali Therapeutics by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company's stock worth $1,210,000 after buying an additional 3,432 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Denali Therapeutics by 58.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company's stock worth $22,732,000 after purchasing an additional 614,555 shares in the last quarter. Empowered Funds LLC grew its stake in Denali Therapeutics by 11.0% in the first quarter. Empowered Funds LLC now owns 20,639 shares of the company's stock worth $281,000 after purchasing an additional 2,052 shares in the last quarter. Woodline Partners LP grew its stake in Denali Therapeutics by 13.5% in the first quarter. Woodline Partners LP now owns 113,517 shares of the company's stock worth $1,543,000 after purchasing an additional 13,517 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Denali Therapeutics by 1.7% in the second quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company's stock worth $2,681,000 after purchasing an additional 3,210 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics News Roundup

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: HC Wainwright slightly raised near‑term EPS estimates (Q3 and Q4 2026) and nudged FY2026 marginally better, and it keeps a "Buy" rating with a $42 price target — a signal of analyst confidence in the pipeline despite losses. HC Wainwright note
• Positive Sentiment: Robert W. Baird raised its price target to $34, which supports upside expectations relative to the current share level and can attract investors looking for re-rating opportunities. Robert W. Baird Raises Price Target
• Neutral Sentiment: A Globe and Mail piece offers broader analyst commentary on DNLI alongside peers — useful context but not new company‑specific catalysts. Analysts Offer Insights (Globe and Mail)
• Neutral Sentiment: Reported short‑interest data appears to contain errors (shows 0 shares / NaN change) and is not meaningful for gauging current short pressure. Investors should treat the short‑interest read as unreliable until corrected.
• Negative Sentiment: Despite the near‑term tweaks, HC Wainwright substantially lowered EPS forecasts for FY2027–FY2030 (large downward revisions to long‑range profitability), which increases uncertainty about the timing of profitability and may weigh on sentiment for a development‑stage biotech. HC Wainwright note

Denali Therapeutics Stock Performance

Shares of DNLI opened at $19.23 on Monday. The firm has a market capitalization of $3.05 billion, a price-to-earnings ratio of -6.47 and a beta of 1.10. The company has a quick ratio of 9.16, a current ratio of 9.16 and a debt-to-equity ratio of 0.01. The stock's 50-day moving average price is $20.31 and its 200 day moving average price is $18.30. Denali Therapeutics Inc. has a 12-month low of $12.02 and a 12-month high of $23.77.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same period in the prior year, the business earned ($0.67) earnings per share. As a group, research analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on DNLI shares. Morgan Stanley lifted their price objective on shares of Denali Therapeutics from $40.00 to $42.00 and gave the stock an "overweight" rating in a report on Thursday, March 26th. Stifel Nicolaus boosted their price objective on Denali Therapeutics from $34.00 to $41.00 and gave the stock a "buy" rating in a research report on Thursday, March 26th. UBS Group assumed coverage on Denali Therapeutics in a research report on Wednesday, January 7th. They issued a "buy" rating for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Denali Therapeutics in a research report on Wednesday, January 21st. Finally, The Goldman Sachs Group upped their price objective on shares of Denali Therapeutics from $35.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, March 26th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $35.00.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.